# A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

> **NCT07282847** · PHASE1,PHASE2 · RECRUITING · sponsor: **AskBio Inc** · enrollment: 12 (estimated)

## Conditions studied

- Pompe Disease (Late-onset)
- Pompe Disease Late-Onset
- LOPD

## Interventions

- **GENETIC:** AB-1009 (GAA Gene)

## Key facts

- **NCT ID:** NCT07282847
- **Lead sponsor:** AskBio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-09
- **Final completion:** 2032-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282847, "A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07282847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*